106 related articles for article (PubMed ID: 18509193)
1. The Koebner-phenomenon in epidermal growth factor receptor inhibitor-induced cutaneous adverse effects.
Gerber PA; Enderlein E; Homey B
J Clin Oncol; 2008 Jun; 26(16):2790-2. PubMed ID: 18509193
[No Abstract] [Full Text] [Related]
2. Sparing of previously irradiated skin from erlotinib-induced acneiform rash.
Yalçin S; Dizdar O; Yalçin B; Gököz O
J Am Acad Dermatol; 2008 Jan; 58(1):178-9. PubMed ID: 18158935
[No Abstract] [Full Text] [Related]
3. Cutaneous adverse effects during therapy with an epidermal growth factor receptor (EGFR) inhibitor.
Santoro F; Cozzani E; Parodi A
J Dermatolog Treat; 2006; 17(3):160-1. PubMed ID: 16854757
[TBL] [Abstract][Full Text] [Related]
4. Temporal dependence of the effect of radiation on erlotinib-induced skin rash.
Lacouture ME; Hwang C; Marymont MH; Patel J
J Clin Oncol; 2007 May; 25(15):2140; author reply 2141. PubMed ID: 17513824
[No Abstract] [Full Text] [Related]
5. Severe acneiform skin reaction during therapy with erlotinib (Tarceva), an epidermal growth factor receptor (EGFR) inhibitor.
Eames T; Landthaler M; Karrer S
Eur J Dermatol; 2007; 17(6):552-3. PubMed ID: 17951151
[No Abstract] [Full Text] [Related]
6. Erlotinib-induced skin rash in patients with non-small-cell lung cancer: pathogenesis, clinical significance, and management.
Tsimboukis S; Merikas I; Karapanagiotou EM; Saif MW; Syrigos KN
Clin Lung Cancer; 2009 Mar; 10(2):106-11. PubMed ID: 19362953
[TBL] [Abstract][Full Text] [Related]
7. Facial hypertrichosis and trichomegaly developing in patients treated with the epidermal growth factor receptor inhibitor erlotinib.
Vergou T; Stratigos AJ; Karapanagiotou EM; Matekovits AE; Dilana KD; Tsimboukis S; Antoniou C; Chasapi V; Syrigos KN
J Am Acad Dermatol; 2010 Aug; 63(2):e56-8. PubMed ID: 20633793
[No Abstract] [Full Text] [Related]
8. Screening for epidermal growth factor receptor mutations in lung cancer.
Rosell R; Moran T; Queralt C; Porta R; Cardenal F; Camps C; Majem M; Lopez-Vivanco G; Isla D; Provencio M; Insa A; Massuti B; Gonzalez-Larriba JL; Paz-Ares L; Bover I; Garcia-Campelo R; Moreno MA; Catot S; Rolfo C; Reguart N; Palmero R; Sánchez JM; Bastus R; Mayo C; Bertran-Alamillo J; Molina MA; Sanchez JJ; Taron M;
N Engl J Med; 2009 Sep; 361(10):958-67. PubMed ID: 19692684
[TBL] [Abstract][Full Text] [Related]
9. Safety profiles of erlotinib therapy in patients with advanced non-small-cell lung cancer.
Hotta K; Kiura K
Expert Rev Anticancer Ther; 2011 Jul; 11(7):991-7. PubMed ID: 21806322
[TBL] [Abstract][Full Text] [Related]
10. Fulminant hepatic failure secondary to erlotinib.
Liu W; Makrauer FL; Qamar AA; Jänne PA; Odze RD
Clin Gastroenterol Hepatol; 2007 Aug; 5(8):917-20. PubMed ID: 17625975
[TBL] [Abstract][Full Text] [Related]
11. [Tyrosine kinase inhibitor erlotinib (Tarceva) improves survival of patients with multiple previous treatments].
Krankenpfl J; 2004; 42(5-6):158. PubMed ID: 15527222
[No Abstract] [Full Text] [Related]
12. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
Johnson JR; Cohen M; Sridhara R; Chen YF; Williams GM; Duan J; Gobburu J; Booth B; Benson K; Leighton J; Hsieh LS; Chidambaram N; Zimmerman P; Pazdur R
Clin Cancer Res; 2005 Sep; 11(18):6414-21. PubMed ID: 16166415
[TBL] [Abstract][Full Text] [Related]
13. The SERIES clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors.
Lacouture ME; Basti S; Patel J; Benson A
J Support Oncol; 2006 May; 4(5):236-8. PubMed ID: 16724647
[No Abstract] [Full Text] [Related]
14. Rosaceiform eruption induced by erlotinib.
Patrizi A; Bianchi F; Neri I
Dermatol Ther; 2008 Oct; 21 Suppl 2():S43-5. PubMed ID: 18837734
[TBL] [Abstract][Full Text] [Related]
15. Radiation-induced prevention of erlotinib-induced skin rash is transient: a new aspect toward the understanding of epidermal growth factor receptor inhibitor associated cutaneous adverse effects.
Gerber PA; Enderlein E; Homey B; Muller A; Boelke E; Budach W
J Clin Oncol; 2007 Oct; 25(29):4697-8; author reply 4698-9. PubMed ID: 17925571
[No Abstract] [Full Text] [Related]
16. Erlotinib: optimizing therapy with predictors of response?
Goodin S
Clin Cancer Res; 2006 May; 12(10):2961-3. PubMed ID: 16707589
[No Abstract] [Full Text] [Related]
17. Erlotinib and maintenance therapy of non-small cell lung cancer. Inadequate assessment; authorisation unjustified.
Prescrire Int; 2011 Oct; 20(120):234. PubMed ID: 21970082
[No Abstract] [Full Text] [Related]
18. Erlotinib-associated skin reactions - case report and proposal for classification.
Zoller A; Schäd SG; Gross GE
Br J Dermatol; 2006 Dec; 155(6):1293-5. PubMed ID: 17107405
[No Abstract] [Full Text] [Related]
19. [Analysis of therapeutic efficacy in 49 patients with advanced non-small cell cancer treated with gefitinib].
Zhang PL; Chen L
Zhonghua Zhong Liu Za Zhi; 2007 Aug; 29(8):635-6. PubMed ID: 18210890
[No Abstract] [Full Text] [Related]
20. Palmar bullous blistering induced by erlotinib.
Berg A; Brustugun OT; Lund-Iversen M; Helland Å
J Thorac Oncol; 2011 May; 6(5):954. PubMed ID: 21623268
[No Abstract] [Full Text] [Related]
[Next] [New Search]
